Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations

Published:2024-11 Issue: Volume:320 Page:124543
ISSN:1386-1425
Container-title:Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
language:en
Short-container-title:Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Author:

Alzhrani Rami M.,Almalki Atiah H.,Alosaimi Manal E.,Algarni Majed A,Abduljabbar Maram H.,Aldawsari Mohammed F.,Alturki Mansour S.,Alsulami Fahad T.,Abdelazim Ahmed H.

Funder

Princess Nourah bint Abdulrahman University

Publisher

Elsevier BV

Reference9 articles.

1. Futibatinib: first approval;Syed;Drugs,2022

2. Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study;Meric-Bernstam;Cancer Discov.,2022

3. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives;Rizzo;Expert Opin. Invest. Drugs,2021

4. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors;Sootome;Cancer Res.,2020

5. Validated UPLC-MS/MS method for determination of futibatinib and its pharmacokinetics in beagle dogs;Li;J. Chem.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP